Logo image of NTRB

NUTRIBAND INC (NTRB) Stock Fundamental Analysis

USA - NASDAQ:NTRB - US67092M2089 - Common Stock

7.63 USD
+0.29 (+3.95%)
Last: 10/14/2025, 8:03:05 PM
Fundamental Rating

4

NTRB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. The financial health of NTRB is average, but there are quite some concerns on its profitability. NTRB is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NTRB has reported negative net income.
In the past year NTRB has reported a negative cash flow from operations.
NTRB had negative earnings in each of the past 5 years.
NTRB had a negative operating cash flow in each of the past 5 years.
NTRB Yearly Net Income VS EBIT VS OCF VS FCFNTRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of NTRB (-315.26%) is worse than 93.33% of its industry peers.
NTRB has a worse Return On Equity (-377.72%) than 76.92% of its industry peers.
Industry RankSector Rank
ROA -315.26%
ROE -377.72%
ROIC N/A
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
NTRB Yearly ROA, ROE, ROICNTRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

The Gross Margin of NTRB (34.36%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of NTRB has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NTRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
NTRB Yearly Profit, Operating, Gross MarginsNTRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NTRB has more shares outstanding
The number of shares outstanding for NTRB has been increased compared to 5 years ago.
The debt/assets ratio for NTRB has been reduced compared to a year ago.
NTRB Yearly Shares OutstandingNTRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
NTRB Yearly Total Debt VS Total AssetsNTRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 25.72 indicates that NTRB is not in any danger for bankruptcy at the moment.
NTRB has a Altman-Z score of 25.72. This is amongst the best in the industry. NTRB outperforms 93.85% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that NTRB is not too dependend on debt financing.
NTRB's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. NTRB outperforms 59.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 25.72
ROIC/WACCN/A
WACC8.68%
NTRB Yearly LT Debt VS Equity VS FCFNTRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M

2.3 Liquidity

A Current Ratio of 4.78 indicates that NTRB has no problem at all paying its short term obligations.
NTRB has a better Current ratio (4.78) than 67.69% of its industry peers.
A Quick Ratio of 4.70 indicates that NTRB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.70, NTRB is in the better half of the industry, outperforming 68.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.78
Quick Ratio 4.7
NTRB Yearly Current Assets VS Current LiabilitesNTRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for NTRB have decreased strongly by -255.00% in the last year.
NTRB shows a strong growth in Revenue. In the last year, the Revenue has grown by 42.93%.
Measured over the past years, NTRB shows a very strong growth in Revenue. The Revenue has been growing by 41.99% on average per year.
EPS 1Y (TTM)-255%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1276.65%
Revenue 1Y (TTM)42.93%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%40.47%

3.2 Future

Based on estimates for the next years, NTRB will show a very strong growth in Earnings Per Share. The EPS will grow by 100.83% on average per year.
The Revenue is expected to grow by 334.01% on average over the next years. This is a very strong growth
EPS Next Y6.67%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue Next Year528.03%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NTRB Yearly Revenue VS EstimatesNTRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
NTRB Yearly EPS VS EstimatesNTRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTRB. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 5.16, which indicates a rather cheap valuation of NTRB.
NTRB's Price/Forward Earnings ratio is rather cheap when compared to the industry. NTRB is cheaper than 95.38% of the companies in the same industry.
NTRB is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.99, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 5.16
NTRB Price Earnings VS Forward Price EarningsNTRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTRB Per share dataNTRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

NTRB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NTRB's earnings are expected to grow with 100.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y110.16%
EPS Next 3Y100.83%

More info and screens

0

5. Dividend

5.1 Amount

NTRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUTRIBAND INC

NASDAQ:NTRB (10/14/2025, 8:03:05 PM)

7.63

+0.29 (+3.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-09 2025-09-09/amc
Earnings (Next)12-02 2025-12-02
Inst Owners2.89%
Inst Owner Change0%
Ins Owners55.75%
Ins Owner Change0%
Market Cap91.79M
Analysts82.86
Price Target15.3 (100.52%)
Short Float %4.09%
Short Ratio1.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.33%
Min EPS beat(2)-3.81%
Max EPS beat(2)26.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.55%
Min Revenue beat(2)-13.5%
Max Revenue beat(2)-1.6%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.16
P/S 35.6
P/FCF N/A
P/OCF N/A
P/B 10.81
P/tB 14.03
EV/EBITDA N/A
EPS(TTM)-2.87
EYN/A
EPS(NY)1.48
Fwd EY19.38%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.21
BVpS0.71
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -315.26%
ROE -377.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.36%
FCFM N/A
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
F-Score4
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.01%
Cap/Sales 2.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.78
Quick Ratio 4.7
Altman-Z 25.72
F-Score4
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-255%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1276.65%
EPS Next Y6.67%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue 1Y (TTM)42.93%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%40.47%
Revenue Next Year528.03%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A
EBIT growth 1Y-7.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.09%
OCF growth 3YN/A
OCF growth 5YN/A